Name | Number of supported studies | Average coverage | |
---|---|---|---|
epithelial cell | 3 studies | 19% ± 2% |
Insufficient scRNA-seq data for expression of APEX2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 1372.41 | 1445 / 1445 | 100% | 45.54 | 183 / 183 |
intestine | 100% | 1216.27 | 966 / 966 | 100% | 51.16 | 527 / 527 |
ovary | 100% | 1315.70 | 180 / 180 | 100% | 44.42 | 430 / 430 |
skin | 100% | 1844.15 | 1809 / 1809 | 100% | 45.96 | 472 / 472 |
stomach | 100% | 984.48 | 359 / 359 | 100% | 48.94 | 286 / 286 |
uterus | 100% | 1175.52 | 170 / 170 | 100% | 60.57 | 459 / 459 |
lung | 100% | 1210.80 | 578 / 578 | 100% | 44.12 | 1153 / 1155 |
bladder | 100% | 1339.43 | 21 / 21 | 100% | 55.89 | 503 / 504 |
thymus | 100% | 1103.09 | 653 / 653 | 100% | 28.66 | 603 / 605 |
kidney | 100% | 1514.74 | 89 / 89 | 100% | 27.72 | 897 / 901 |
breast | 100% | 1217.12 | 459 / 459 | 100% | 49.50 | 1113 / 1118 |
liver | 100% | 935.97 | 226 / 226 | 100% | 25.44 | 404 / 406 |
prostate | 100% | 1297.54 | 245 / 245 | 99% | 30.69 | 499 / 502 |
pancreas | 99% | 668.49 | 325 / 328 | 100% | 37.84 | 178 / 178 |
brain | 99% | 553.47 | 2611 / 2642 | 100% | 23.53 | 705 / 705 |
adrenal gland | 100% | 1337.84 | 258 / 258 | 97% | 26.80 | 223 / 230 |
adipose | 100% | 1150.87 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 30.15 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 64.63 | 29 / 29 |
spleen | 100% | 1748.71 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 54.73 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 31.99 | 1 / 1 |
blood vessel | 100% | 1031.66 | 1334 / 1335 | 0% | 0 | 0 / 0 |
heart | 99% | 824.78 | 856 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 98% | 1306.87 | 909 / 929 | 0% | 0 | 0 / 0 |
muscle | 97% | 709.64 | 780 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006310 | Biological process | DNA recombination |
GO_0006284 | Biological process | base-excision repair |
GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
GO_0001650 | Cellular component | fibrillar center |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005739 | Cellular component | mitochondrion |
GO_0005634 | Cellular component | nucleus |
GO_0003906 | Molecular function | DNA-(apurinic or apyrimidinic site) endonuclease activity |
GO_0003677 | Molecular function | DNA binding |
GO_0008311 | Molecular function | double-stranded DNA 3'-5' DNA exonuclease activity |
GO_0008081 | Molecular function | phosphoric diester hydrolase activity |
GO_0005515 | Molecular function | protein binding |
GO_0004519 | Molecular function | endonuclease activity |
GO_0008270 | Molecular function | zinc ion binding |
Gene name | APEX2 |
Protein name | Alternative protein APEX2 DNA-(apurinic or apyrimidinic site) endonuclease (EC 3.1.-.-) DNA-(apurinic or apyrimidinic site) endonuclease 2 (EC 3.1.11.2) DNA-(apurinic or apyrimidinic site) endonuclease 2 (EC 3.1.11.2) (AP endonuclease XTH2) (APEX nuclease 2) (APEX nuclease-like 2) (Apurinic-apyrimidinic endonuclease 2) (AP endonuclease 2) |
Synonyms | XTH2 APEXL2 APE2 hCG_18950 |
Description | FUNCTION: Functions as a weak apurinic/apyrimidinic (AP) endodeoxyribonuclease in the DNA base excision repair (BER) pathway of DNA lesions induced by oxidative and alkylating agents . Initiates repair of AP sites in DNA by catalyzing hydrolytic incision of the phosphodiester backbone immediately adjacent to the damage, generating a single-strand break with 5'-deoxyribose phosphate and 3'-hydroxyl ends. Also displays double-stranded DNA 3'-5' exonuclease, 3'-phosphodiesterase activities . Shows robust 3'-5' exonuclease activity on 3'-recessed heteroduplex DNA and is able to remove mismatched nucleotides preferentially . Also exhibits 3'-5' exonuclease activity on a single nucleotide gap containing heteroduplex DNA and on blunt-ended substrates . Shows fairly strong 3'-phosphodiesterase activity involved in the removal of 3'-damaged termini formed in DNA by oxidative agents . In the nucleus functions in the PCNA-dependent BER pathway . Plays a role in reversing blocked 3' DNA ends, problematic lesions that preclude DNA synthesis . Required for somatic hypermutation (SHM) and DNA cleavage step of class switch recombination (CSR) of immunoglobulin genes (By similarity). Required for proper cell cycle progression during proliferation of peripheral lymphocytes (By similarity). . FUNCTION: Initiates repair of AP sites in DNA by catalyzing hydrolytic incision of the phosphodiester backbone immediately adjacent to the damage, generating a single-strand break with 5'-deoxyribose phosphate and 3'-hydroxyl ends. . |
Accessions | Q9UBZ4 B7ZA71 E5KN95 ENST00000374987.4 L8E820 |